Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
As Amgen prepares to report earnings, analysts are divided on the stock's trajectory. While strategic acquisitions and a solid track record fuel optimism, looming competitive pressures and a key pipeline wait temper expectations.
Ford Motor Company is reportedly in preliminary discussions with Chinese tech and auto newcomer Xiaomi, exploring a joint venture that could facilitate Xiaomi's entry into U.S. vehicle manufacturing, according to sources familiar with the matter.
Beijing has lowered punitive tariffs on key EU dairy products, offering some relief to exporters like Arla and Lactalis. While welcomed as a de-escalation, European trade bodies argue the remaining duties are unjustified and call for continued negotiations to resolve the trade dispute.
Chinese courts have executed four senior members of a Myanmar-based criminal organization for murder, trafficking, and running a multi-billion dollar scam operation that exploited thousands, including Chinese citizens. The move is part of a broader crackdown on cross-border cyber fraud hubs.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Chinese courts have executed four individuals convicted of running a multi-billion dollar scam and gambling network from Myanmar, responsible for multiple deaths. The move signals Beijing's escalating pressure on Southeast Asia's industrial-scale cybercrime hubs.
UK Labour leader Keir Starmer urges sustained engagement with Beijing, countering Donald Trump's call for Western disengagement and highlighting deepening geopolitical divides.
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.
Travere Therapeutics faces a securities fraud investigation by Robbins Geller Rudman & Dowd LLP, raising questions about the accuracy of its past disclosures. The probe casts a shadow over the company's critical transition, as it banks on its kidney drug FILSPARI to drive growth amid mounting legal and commercial pressures.
Chinese authorities have executed four individuals convicted of running a multi-billion dollar telecom fraud and gambling network from Myanmar, responsible for six deaths. The move follows last week's execution of 11 others, signaling Beijing's intensifying campaign against organized cybercrime in Southeast Asia.
Backed by a major U.S. government loan and a surge in private equity, USA Rare Earth is accelerating its domestic mining and manufacturing projects, positioning itself at the forefront of a critical national strategy.
Chinese authorities have executed four individuals convicted of leading a massive online fraud and gambling ring based in Myanmar, linked to over $4 billion in illicit proceeds and the deaths of six Chinese nationals. The move is part of a widening crackdown on cross-border criminal networks targeting Chinese citizens.
A renewed emphasis by President Xi Jinping on building a 'strong financial nation' with a globally powerful currency is being interpreted as a signal for accelerated yuan internationalization, as global confidence in the dollar shows signs of strain.
As Amgen prepares to release its fourth-quarter results, investors are watching for signs of sustained momentum in its key drug portfolios and the impact of recent acquisitions.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Baidu's flagship AI assistant, Ernie, has surpassed 200 million monthly active users, a milestone reported by the Wall Street Journal. The growth underscores Baidu's deepening integration of AI across its ecosystem amid fierce competition with domestic tech rivals.
In a significant policy shift, Chinese authorities have reportedly cleared the AI startup DeepSeek to purchase Nvidia's advanced H200 processors, potentially easing a major hardware bottleneck for its competitive large language model.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
